Method and compositions for identifying anti-HIV therapeutic compounds
申请人:Arimilli N. Murty
公开号:US20050239054A1
公开(公告)日:2005-10-27
Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.
Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds
申请人:Arimilli N. Murty
公开号:US20050209197A1
公开(公告)日:2005-09-22
Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.
Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds
申请人:Arimilli N. Murty
公开号:US20070010489A1
公开(公告)日:2007-01-11
Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit 5 HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.
The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.
该发明提供了制备包括从本文所述的SEQ ID NOs:1-249中选择的GCC激动剂序列的肽的过程。
Nebivolol and its Pharmaceutically Acceptable Salts, Process for Preparation and Pharmaceutical Compositions of Nebivolol
申请人:Forest Laboratories Holdings Limited
公开号:US20130296583A1
公开(公告)日:2013-11-07
The present invention provides an improved process for the synthesis of nebivolol or its pharmaceutically acceptable salts, more particularly hydrochloride salt of formula (I).
The present invention further provides a new Form T1 of nebivolol and its pharmaceutically acceptable salts.
The present invention also provides pharmaceutical compositions and process for the preparation of a solid oral dosage form of nebivolol hydrochloride of formula (I), without the use of wetting agent, and optionally using binder and/or disintegrant.